Skip to main content
. 2020 Sep 3;75(12):1112–1115. doi: 10.1136/thoraxjnl-2020-214656

Figure 3.

Figure 3

Protection of mice against influenza challenge mediated by rSIV.F/HN is comparable to protection offered by rAAV8 or rAAV9. Mice (BALB/c, n=5–6 per group) were dosed with rSIV.F/HN.hCEF.T13B (2.7e8 TU, magenta), rSIV.F/HN.hCEF.GLux (1e8 TU black) or rAAV2/9.hCEFI.T13B (1e11 GCs, green) via intranasal instillation, or with rAAV2/8.CASI.T13B (1e11 GC, purple) delivered via intramuscular injection. After 1 month, mice were challenged with 10 LD50 of H1N1 A/PR/8/1934 (Cambridge). Body weight (A) was measured daily for 14 days and mice were euthanised if weight loss declined ≥20% as depicted in the Kaplan-Meier survival curve (B). GCs, genome copies; rAAV, recombinant adeno-associated virus; SIV, simian immunodeficiency virus; TU, transducing units.